Open Access Open Access  Restricted Access Subscription or Fee Access

Types, Regulations, and Clinical Benefits of Cell Therapy

Vikrant Singh, Ajay Kumar, Akshay Yadav, Chitra .

Abstract


Cell treatment has been practised since the late nineteenth century and continues to grow as a result of research and funding. Cell therapy encompasses stem cell and non-stem cell-based therapies, as well as multicellular and unicellular therapies, all of which have varied immune-phenotypic profiles, methods of treatment, separation procedures and regulation levels. Kinds of tissue engineering, encompassing stem cell-based or non-stem cell-based cell therapies, listing the first-ever list of multi-cell treatments used in medical circumstances. We go over the benefits of cell treatments in three different therapeutic categories: Immunological diseases, regenerative medicines, immunological illnesses, and oncology, in addition to the nuts and bolts of FDA policies controlling their use. We also explore the increasing focus on combination therapy strategies, emphasising the features that make multicellular therapies more desirable than their unicellular counterparts.


Keywords


Cell treatment, Therapy, Clinical, Regulations, Tissue engineering

Full Text:

PDF

References


Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. (2008) 454: 766–70.

Ying QL, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, et al. The ground state of embryonic stem cell self-renewal. Nature. (2008) 453: 519–23.

Nichols J, Smith A. Naive and primed pluripotent states. Cell Stem Cell. (2009) 4:487–92.

Chu DT, Nguyen TT, Tien NLB, Tran DK, Jeong JH, Anh PG, et al. Recent Progress of stem cell therapy in cancer treatment: molecular mechanisms and potential applications. Cells. (2020) 9: 563.

Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. (1981) 292: 154–6.

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. (1998) 282: 1145–7.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. (2006) 126: 663–76.

Poulos J. The limited application of stem cells in medicine: a review. Stem Cell Res Ther. (2018) 9:1.

Wysoczynski M. A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair. Eur Heart J. (2020) 41: 2397–404B.

Schwartz SD, Hubschman JP, Heilwell G, Franco-Cardenas V, Pan CK, Ostrick RM, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet. (2012) 379: 713–20.

Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Cacciapuoti I, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. (2015) 36: 2011–7.

Bragança J, Lopes JA, Mendes-Silva L, Santos JMA. Induced pluripotent stem cells, a giant leap for mankind therapeutic applications. World J Stem Cells. (2019) 11: 421–30.

Kavyasudha C, Macrin D, ArulJothi KN, Joseph JP, Harishankar MK, Devi A. Clinical applications of induced pluripotent stem cells–stato attuale. Adv Exp Med Biol. (2018) 1079: 127–49.

Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell–derived retinal cells for macular degeneration. N Engl J Med. (2017) 376: 1038–46.

Chagastelles PC, Nardi NB. Biology of stem cells: an overview. Kidney Int Suppl. (2011) 1:

–7.

NIH Stem Cell Information Home Page. The Adult Stem Cell. Bethesda, MD (2016).

Gurusamy N, Alsayari A, Rajasingh

S, Rajasingh J. Adult stem cells for regenerative therapy. Prog Mol Biol Transl Sci. (2018) 160: 1–22.




DOI: https://doi.org/10.37628/ijcbcp.v8i1.774

Refbacks

  • There are currently no refbacks.